• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国病变可见性预测系统活检前列腺癌的临床显著升级。

US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy.

机构信息

Department of Radiology, University of California, San Francisco, San Francisco, CA, USA.

Department of Radiology, Urology, and Radiation Oncology, University of Washington, Seattle, WA, USA.

出版信息

Abdom Radiol (NY). 2022 Mar;47(3):1133-1141. doi: 10.1007/s00261-021-03389-x. Epub 2022 Jan 7.

DOI:10.1007/s00261-021-03389-x
PMID:34997299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8863714/
Abstract

PURPOSE

To identify predictors of when systematic biopsy leads to a higher overall prostate cancer grade compared to targeted biopsy.

METHODS AND MATERIALS

918 consecutive patients who underwent prostate MRI followed by MRI/US fusion biopsy and systematic biopsies from January 2015 to November 2019 at a single academic medical center were retrospectively identified. The outcome was upgrade of PCa by systematic biopsy, defined as cases when systematic biopsy led to a Gleason Grade (GG) ≥ 2 and greater than the maximum GG detected by targeted biopsy. Generalized linear regression and conditional logistic regression were used to analyze predictors of upgrade.

RESULTS

At the gland level, the presence of an US-visible lesion was associated with decreased upgrade (OR 0.64, 95% CI 0.44-0.93, p = 0.02). At the sextant level, upgrade was more likely to occur through the biopsy of sextants with MRI-visible lesions (OR 2.58, 95% CI 1.87-3.63, p < 0.001), US-visible lesions (OR 1.83, 95% CI 1.14-2.93, p = 0.01), and ipsilateral lesions (OR 3.89, 95% CI 2.36-6.42, p < 0.001).

CONCLUSION

Systematic biopsy is less valuable in patients with an US-visible lesion, and more likely to detect upgrades in sextants with imaging abnormalities. An approach that takes additional samples from regions with imaging abnormalities may provide analogous information to systematic biopsy.

摘要

目的

确定系统活检与靶向活检相比导致前列腺癌整体分级升高的预测因素。

方法和材料

回顾性分析了 2015 年 1 月至 2019 年 11 月在一家学术医疗中心接受前列腺 MRI 检查、MRI/US 融合活检和系统活检的 918 例连续患者。主要结局为系统活检导致前列腺癌升级,定义为系统活检导致 Gleason 分级(GG)≥2 且高于靶向活检检测到的最大 GG。采用广义线性回归和条件逻辑回归分析预测升级的因素。

结果

在腺体水平上,US 可见病变的存在与升级降低相关(OR 0.64,95%CI 0.44-0.93,p=0.02)。在六区分区水平上,通过活检 MRI 可见病变(OR 2.58,95%CI 1.87-3.63,p<0.001)、US 可见病变(OR 1.83,95%CI 1.14-2.93,p=0.01)和同侧病变(OR 3.89,95%CI 2.36-6.42,p<0.001)的六分区发生升级的可能性更大。

结论

在 US 可见病变患者中,系统活检的价值较低,而在影像学异常的六分区中更有可能检测到升级。从影像学异常的区域采集额外样本的方法可能提供与系统活检类似的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8863714/b87eb93a06d0/261_2021_3389_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8863714/5896a1866a1d/261_2021_3389_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8863714/b87eb93a06d0/261_2021_3389_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8863714/5896a1866a1d/261_2021_3389_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/818d/8863714/b87eb93a06d0/261_2021_3389_Fig2_HTML.jpg

相似文献

1
US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy.美国病变可见性预测系统活检前列腺癌的临床显著升级。
Abdom Radiol (NY). 2022 Mar;47(3):1133-1141. doi: 10.1007/s00261-021-03389-x. Epub 2022 Jan 7.
2
Targets missed: predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy.未命中目标:系统活检发现前列腺癌的 MRI 靶向活检未能准确定位的预测因素。
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):549-555. doi: 10.1038/s41391-018-0062-9. Epub 2018 Jul 9.
3
Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3 + 4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy.经直肠超声引导下磁共振融合靶向活检预测有临床意义前列腺癌(Gleason 评分 3+4 或更高)中病灶可视性的影响。
J Urol. 2018 Mar;199(3):699-705. doi: 10.1016/j.juro.2017.09.075. Epub 2017 Sep 20.
4
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.与系统性经直肠超声12针穿刺活检相比,磁共振成像/超声融合活检能显著提升前列腺癌的诊断水平。
Eur Urol. 2013 Nov;64(5):713-719. doi: 10.1016/j.eururo.2013.05.059. Epub 2013 Jun 12.
5
Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification.联合 MRI 靶向和系统前列腺活检可能高估最终手术病理的 Gleason 分级,并影响风险分层。
Urol Oncol. 2022 Feb;40(2):59.e1-59.e5. doi: 10.1016/j.urolonc.2021.07.027. Epub 2021 Sep 17.
6
Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.多参数磁共振成像可排除主动监测患者的前列腺癌进展:一项回顾性队列研究。
Eur Radiol. 2020 Nov;30(11):6042-6051. doi: 10.1007/s00330-020-06997-1. Epub 2020 Jun 26.
7
[Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].[实时MRI/超声融合引导下对初诊及活检前疑似前列腺癌患者进行活检]
Aktuelle Urol. 2015 Jan;46(1):34-8. doi: 10.1055/s-0034-1395563. Epub 2014 Dec 17.
8
Multiparametric MRI in detection and staging of prostate cancer.多参数磁共振成像在前列腺癌检测与分期中的应用
Dan Med J. 2017 Feb;64(2).
9
Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?多参数磁共振成像-经直肠超声融合活检时指数病变的饱和活检是否有助于从前列腺活检升级为根治性前列腺切除术病理?
J Urol. 2018 Apr;199(4):976-982. doi: 10.1016/j.juro.2017.10.048. Epub 2018 Jan 20.
10
Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.经会阴模板饱和前列腺活检与磁共振成像靶向活检联合磁共振成像-超声融合引导的比较分析。
J Urol. 2015 Jan;193(1):87-94. doi: 10.1016/j.juro.2014.07.098. Epub 2014 Jul 28.

引用本文的文献

1
Visibility of mpMRI region of interest on ultrasound during cognitive fusion targeted biopsy predicts prostate cancer detection: a prospective single-center study.认知融合靶向活检期间超声下磁共振多参数成像感兴趣区域的可视性预测前列腺癌的检出:一项前瞻性单中心研究
Abdom Radiol (NY). 2024 Dec 23. doi: 10.1007/s00261-024-04750-6.
2
Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI.混合监督的组织病理学可改善 MRI 对前列腺癌的分类。
IEEE Trans Med Imaging. 2024 Jul;43(7):2610-2622. doi: 10.1109/TMI.2024.3382909. Epub 2024 Jul 1.

本文引用的文献

1
MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.MRI 靶向、系统和联合活检在前列腺癌诊断中的应用。
N Engl J Med. 2020 Mar 5;382(10):917-928. doi: 10.1056/NEJMoa1910038.
2
Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.MRI 阴性男性中漏诊有临床意义前列腺癌的预测因素:系统评价和荟萃分析。
J Urol. 2020 Jul;204(1):24-32. doi: 10.1097/JU.0000000000000757. Epub 2020 Jan 22.
3
Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience.
高强度聚焦超声或冷冻消融治疗局限性前列腺癌:单中心经验。
J Urol. 2020 Feb;203(2):320-330. doi: 10.1097/JU.0000000000000506. Epub 2019 Aug 22.
4
Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Biopsy Improves but Does Not Replace Standard Template Biopsy for the Detection of Prostate Cancer.多参数磁共振成像-超声融合活检提高但不能替代标准模板活检用于前列腺癌的检测。
J Urol. 2019 Nov;202(5):944-951. doi: 10.1097/JU.0000000000000359. Epub 2019 Oct 9.
5
Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.在有和没有 mpMRI 可见病变的区域中,使用 PIRADS v2 评分、PSA 密度和 ADC 值检测临床显著前列腺癌。
Int Braz J Urol. 2019 Jul-Aug;45(4):713-723. doi: 10.1590/S1677-5538.IBJU.2018.0768.
6
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌(2019 年版)》,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.
7
Prostate cancer detection rate according to lesion visibility using ultrasound and MRI.基于超声和 MRI 下病灶可视性的前列腺癌检出率。
Clin Radiol. 2019 Jun;74(6):474-479. doi: 10.1016/j.crad.2019.02.002. Epub 2019 Mar 4.
8
Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.通过多参数磁共振成像检测个体前列腺癌病灶。
Eur Urol. 2019 May;75(5):712-720. doi: 10.1016/j.eururo.2018.11.031. Epub 2018 Dec 1.
9
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.基于多参数 MRI 的前列腺系统和靶向活检在初次活检患者中的应用(MRI-FIRST):一项前瞻性、多中心、配对诊断研究。
Lancet Oncol. 2019 Jan;20(1):100-109. doi: 10.1016/S1470-2045(18)30569-2. Epub 2018 Nov 21.
10
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.MRI 靶向或标准活检用于前列腺癌诊断。
N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.